Low molecular weight heparin in the treatment of early fetal growth restriction – a Randomized Controlled Trial

Conditions

Fetal Growth Restriction

Brief summary

Gestational age at delivery

Detailed description

Evolution of fetal Doppler parameters (umbilical artery pulsatility index, middle cerebral artery pulsatility index, cerebralplacental ratio, ductus venosus pulsatility index), Evolution of maternal doppler parameters (uterine artery pulsatility index), Maternal body mass index (BMI) at moment of randomization, Newborn weight, percentile, umbilical artery pH and Apgar score in the 5th minute, Neonatal intensive care admission and duration of admission, A composite outcome of severe neonatal morbidity (evidence of one or more of: intraventricular hemorrhage grade 3 or 4; cystic periventricular leukomalacia; chronic lung disease; retinopathy of prematurity requiring treatment; necrotizing enterocolitis requiring surgery), Gestational hypertension or preeclampsia, Placental abruption, Antepartum hemorrhage, Maternal thrombocytopenia (platelets < 100 000 x 109/L), Stillbirth, Mode of delivery, Indication for delivery, Postpartum hemorrhage, Placental pathology, sFLT1-PLGF ratio, Syncytiotrophoblast derived vesicles (STD-EVS)

Related papers

No related papers found yet.

Interventions

DRUGEnoxaparina Rovi 4.000 UI (40 mg)/0

DRUG4 mL solução injetável em seringa pré-cheia

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Gestational age at delivery	—

Secondary

Measure	Time frame
Evolution of fetal Doppler parameters (umbilical artery pulsatility index, middle cerebral artery pulsatility index, cerebralplacental ratio, ductus venosus pulsatility index), Evolution of maternal doppler parameters (uterine artery pulsatility index), Maternal body mass index (BMI) at moment of randomization, Newborn weight, percentile, umbilical artery pH and Apgar score in the 5th minute, Neonatal intensive care admission and duration of admission, A composite outcome of severe neonatal morbidity (evidence of one or more of: intraventricular hemorrhage grade 3 or 4; cystic periventricular leukomalacia; chronic lung disease; retinopathy of prematurity requiring treatment; necrotizing enterocolitis requiring surgery), Gestational hypertension or preeclampsia, Placental abruption, Antepartum hemorrhage, Maternal thrombocytopenia (platelets < 100 000 x 109/L), Stillbirth, Mode of delivery, Indication for delivery, Postpartum hemorrhage, Placental pathology, sFLT1-PLGF ratio, Syncytiotr	—

Measure

Time frame

Evolution of fetal Doppler parameters (umbilical artery pulsatility index, middle cerebral artery pulsatility index, cerebralplacental ratio, ductus venosus pulsatility index), Evolution of maternal doppler parameters (uterine artery pulsatility index), Maternal body mass index (BMI) at moment of randomization, Newborn weight, percentile, umbilical artery pH and Apgar score in the 5th minute, Neonatal intensive care admission and duration of admission, A composite outcome of severe neonatal morbidity (evidence of one or more of: intraventricular hemorrhage grade 3 or 4; cystic periventricular leukomalacia; chronic lung disease; retinopathy of prematurity requiring treatment; necrotizing enterocolitis requiring surgery), Gestational hypertension or preeclampsia, Placental abruption, Antepartum hemorrhage, Maternal thrombocytopenia (platelets < 100 000 x 109/L), Stillbirth, Mode of delivery, Indication for delivery, Postpartum hemorrhage, Placental pathology, sFLT1-PLGF ratio, Syncytiotr

—

Countries

Portugal

Outcome results

None listed